Production (Stage)
Ginkgo Bioworks Holdings, Inc.
DNA
$7.25
-$0.17-2.29%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 15.42% | -90.65% | 74.03% | -30.90% | 21.63% |
| Total Depreciation and Amortization | -1.83% | -8.84% | -0.93% | 34.66% | 0.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -24.61% | 39.95% | -69.18% | 72.65% | -35.87% |
| Change in Net Operating Assets | -630.75% | 102.22% | -1,767.36% | 1,784.62% | -99.26% |
| Cash from Operations | -21.41% | 59.00% | -22.65% | 5.45% | -54.34% |
| Capital Expenditure | 44.41% | 9.14% | 44.18% | -302.86% | -94.72% |
| Sale of Property, Plant, and Equipment | -- | -85.75% | 109.42% | -- | -- |
| Cash Acquisitions | -- | -- | -- | 100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -33,737.68% | -87.35% | -- | -- | -- |
| Cash from Investing | -1,418.41% | -28.28% | 62.00% | -121.64% | 74.05% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.97% | -1.50% | 0.00% | 31.97% | 7.55% |
| Issuance of Common Stock | -- | -- | -100.00% | -80.00% | 400.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -562.50% | 93.56% | -103.61% |
| Cash from Financing | -1.97% | 56.34% | -105.75% | 73.25% | -33.70% |
| Foreign Exchange rate Adjustments | 201.37% | -108.57% | -118.75% | 89.81% | -253.92% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -348.67% | 51.14% | -2.45% | -8.89% | 2.54% |